BlinkLab Commences Pivotal FDA 510(k) Validation Program with First Participant Enrolment

BlinkLab (ASX: BB1) has initiated its pivotal FDA 510(k) validation program for its pediatric autism diagnostic aid, BlinkLab Dx1, marking a critical step towards regulatory submission with the enrolment of its first participant.

The program is specifically designed to generate the core clinical and usability evidence required for a planned FDA 510(k) submission for the company's BlinkLab Dx1 pediatric autism diagnostic aid.

The study structure begins with a dedicated usability phase that confirms clinicians and caregivers can safely and effectively use the platform in real-world settings.

It will then transition into a double-blinded, multi-centre clinical validation.

Expert contract research organisation IQVIA-MCRA is leading and conducting the study, ensuring adherence to rigorous protocols, data quality standards, and regulatory requirements.

The main study is conducted across 10 US clinical sites, including multiple leading paediatric and autism centres.

Regulatory Pathway Advancing

The enrollment of the first participant is a key advancement in BlinkLab's regulatory pathway that moves the company closer to its targeted FDA submission by end-2026.

A pilot study for BlinkLab Dx1 demonstrated strong diagnostic performance, achieving a sensitivity of 83.7% and a specificity of 84.7%.

These results materially exceeded the target sensitivity and specificity thresholds of 65% for both metrics.

Previous coverage has indicated that the 510(k) submission is targeted for H2 CY2026, aligning with the company's current projections.

Study Execution and Timeline

BlinkLab anticipates that recruitment for the validation program will take approximately 8 months.

Following this, the FDA 510(k) submission is targeted for year-end 2026.

This commencement follows BlinkLab's earlier announcement regarding the completion of its 10-site pivotal FDA study network.

This network was established ahead of the trial's March 2026 start, demonstrating systematic progress towards this regulatory milestone.

Outlook

Initiation of the pivotal validation program with first participant enrollment is a key de-risking event for BlinkLab's regulatory submission timeline.

Continued progress in patient recruitment and successful generation of clinical evidence are critical for achieving the targeted end-2026 FDA 510(k) submission.